Skip to main content
Erschienen in: Annals of Surgical Oncology 11/2010

01.11.2010 | Breast Oncology

Present-Day Locoregional Control in Patients with T1 or T2 Breast Cancer with 0 and 1 to 3 Positive Lymph Nodes After Mastectomy Without Radiotherapy

verfasst von: Ranjna Sharma, MD, Isabelle Bedrosian, MD, Anthony Lucci, MD, Rosa F. Hwang, MD, Loren L. Rourke, MD, Wei Qiao, MS, Thomas A. Buchholz, MD, Steven J. Kronowitz, MD, Savitri Krishnamurthy, MD, Gildy V. Babiera, MD, Ana M. Gonzalez-Angulo, MD, Funda Meric-Bernstam, MD, Elizabeth A. Mittendorf, MD, Kelly K. Hunt, MD, Henry M. Kuerer, MD, PhD, FACS

Erschienen in: Annals of Surgical Oncology | Ausgabe 11/2010

Einloggen, um Zugang zu erhalten

Abstract

Background

We sought to determine present-day locoregional recurrence (LRR) rates to better understand the role of postmastectomy radiotherapy (PMRT) in women with 0 to 3 positive lymph nodes.

Methods

Clinical and pathologic factors were identified for 1019 patients with pT1 or pT2 tumors and 0 (n = 753), 1 (n = 176), 2 (n = 69), or 3 (n = 21) positive lymph nodes treated with mastectomy without PMRT during 1997 to 2002. Total LRR rates were calculated by Kaplan-Meier analysis and compared between subgroups by the log rank test.

Results

After a median follow-up of 7.47 years, the overall 10-year LRR rate was 2.7%. The only independent predictor of LRR was younger age (P = 0.004). Patients ≤40 years old had a 10-year LRR rate of 11.3 vs. 1.5% for older patients (P < 0.0001). The 10-year rate of LRR in patients with 1 to 3 positive nodes was 4.3% (94.4% had systemic therapy), which was not significantly different from the 10-year risk of contralateral breast cancer development (6.5%; P > 0.5). Compared with the 10-year LRR rate among patients with node-negative disease (2.1%), patients with 1 positive node had a similar 10-year LRR risk (3.3%; P > 0.5), and patients with 2 positive nodes had a 10-year LRR risk of 7.9% (P = 0.0003). Patients with T2 tumors with 1 to 3 positive nodes had a 10-year LRR rate of 9.7%.

Conclusions

In patients with T1 and T2 breast cancer with 0 to 3 positive nodes, LRR rates after mastectomy are low, with the exception of patients ≤40 years old. The indications for PMRT in patients treated in the current era should be reexamined.
Literatur
1.
Zurück zum Zitat Overgaard M, Hansen PS, Overgaard J, et al. Postmastectomy irradiation in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. N Engl J Med. 1997;337:949–55.CrossRefPubMed Overgaard M, Hansen PS, Overgaard J, et al. Postmastectomy irradiation in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. N Engl J Med. 1997;337:949–55.CrossRefPubMed
2.
Zurück zum Zitat Ragaz J, Jackson SM, Le N, et al. Adjuvant radiotherapy and chemotherapy in node positive premenopausal women with breast cancer. N Engl J Med. 1997;337:956–62.CrossRefPubMed Ragaz J, Jackson SM, Le N, et al. Adjuvant radiotherapy and chemotherapy in node positive premenopausal women with breast cancer. N Engl J Med. 1997;337:956–62.CrossRefPubMed
3.
Zurück zum Zitat Whelan TJ, Julian J, Wright J, Jadad AR, Levine M. Does locoregional radiation therapy improve survival in breast cancer? A meta-analysis. J Clin Oncol. 2000;18:1220–9.PubMed Whelan TJ, Julian J, Wright J, Jadad AR, Levine M. Does locoregional radiation therapy improve survival in breast cancer? A meta-analysis. J Clin Oncol. 2000;18:1220–9.PubMed
4.
Zurück zum Zitat Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366:2087–106.PubMed Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366:2087–106.PubMed
5.
Zurück zum Zitat Katz A, Strom EA, Buchholz TA, et al. Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: implications for postoperative irradiation. J Clin Oncol. 2000;18:2817–27.PubMed Katz A, Strom EA, Buchholz TA, et al. Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: implications for postoperative irradiation. J Clin Oncol. 2000;18:2817–27.PubMed
6.
Zurück zum Zitat Wallgren A, Bonetti M, Gelber RD, et al. Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII. J Clin Oncol. 2003;21:1205–13.CrossRefPubMed Wallgren A, Bonetti M, Gelber RD, et al. Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII. J Clin Oncol. 2003;21:1205–13.CrossRefPubMed
8.
Zurück zum Zitat Recht A, Gray R, Davidson NE, et al. Locoregional failure ten years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group. J Clin Oncol. 1999;17:1689–700.PubMed Recht A, Gray R, Davidson NE, et al. Locoregional failure ten years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group. J Clin Oncol. 1999;17:1689–700.PubMed
9.
Zurück zum Zitat Katz A, Strom EA, Buchholz TA, et al. The influence of pathologic tumor characteristics on locoregional recurrence rates following mastectomy. Int J Radiat Oncol Biol Phys. 2001;50:735–42.CrossRefPubMed Katz A, Strom EA, Buchholz TA, et al. The influence of pathologic tumor characteristics on locoregional recurrence rates following mastectomy. Int J Radiat Oncol Biol Phys. 2001;50:735–42.CrossRefPubMed
10.
Zurück zum Zitat Truong PT, Olivotto IA, Kader HA, et al. Selecting breast cancer patients with T1–T2 tumors and one to three positive axillary nodes at high postmastectomy locoregional recurrence risk for adjuvant radiotherapy. Int J Radiat Oncol Biol Phys. 2005;61:1337–47.PubMed Truong PT, Olivotto IA, Kader HA, et al. Selecting breast cancer patients with T1–T2 tumors and one to three positive axillary nodes at high postmastectomy locoregional recurrence risk for adjuvant radiotherapy. Int J Radiat Oncol Biol Phys. 2005;61:1337–47.PubMed
11.
Zurück zum Zitat Overgaard M, Nielsen HM, Overgaard J. Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. Radiother Oncol. 2007;82:247–53.CrossRefPubMed Overgaard M, Nielsen HM, Overgaard J. Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. Radiother Oncol. 2007;82:247–53.CrossRefPubMed
12.
Zurück zum Zitat Ragaz J, Olivotto IA, Spinelli J, et al. Locoregional radiation therapy in patients with high risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia Randomised Trial. J Natl Cancer Inst. 2005;97:116–26.CrossRefPubMed Ragaz J, Olivotto IA, Spinelli J, et al. Locoregional radiation therapy in patients with high risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia Randomised Trial. J Natl Cancer Inst. 2005;97:116–26.CrossRefPubMed
13.
Zurück zum Zitat Taghian A, Jeong J-H, Mamounas, et al. Patterns of locoregional failure in patients with cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical adjuvant Breast and Bowel Project Randomized Clinical Trials. J Clin Oncol. 2004;21:4247–54.CrossRef Taghian A, Jeong J-H, Mamounas, et al. Patterns of locoregional failure in patients with cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical adjuvant Breast and Bowel Project Randomized Clinical Trials. J Clin Oncol. 2004;21:4247–54.CrossRef
15.
Zurück zum Zitat Jacobs LK, Balch CM, Soong SJ. Predicting the risk of axillary nodal metastases and their use in selecting breast surgery options. J Clin Oncol. 2009;27:5673–5.CrossRefPubMed Jacobs LK, Balch CM, Soong SJ. Predicting the risk of axillary nodal metastases and their use in selecting breast surgery options. J Clin Oncol. 2009;27:5673–5.CrossRefPubMed
16.
Zurück zum Zitat Kronowitz SJ, Kuerer HM. Advances and surgical decision-making for breast reconstruction. Cancer. 2006;107:897–907.CrossRef Kronowitz SJ, Kuerer HM. Advances and surgical decision-making for breast reconstruction. Cancer. 2006;107:897–907.CrossRef
17.
Zurück zum Zitat Kronowitz SJ, Hunt KK, Kuerer HM, et al. Delayed-immediate breast reconstruction. Plast Reconstr Surg. 2004;113:1617–28.CrossRefPubMed Kronowitz SJ, Hunt KK, Kuerer HM, et al. Delayed-immediate breast reconstruction. Plast Reconstr Surg. 2004;113:1617–28.CrossRefPubMed
18.
Zurück zum Zitat Jagsi R, Raad RA, Goldberg S, et al. Locoregional recurrence rates and prognostic factors for failure in node-negative patients treated with mastectomy: implications for postmastectomy radiation. Int J Radiat Oncol Biol Phys. 2005;62:1035–9.PubMed Jagsi R, Raad RA, Goldberg S, et al. Locoregional recurrence rates and prognostic factors for failure in node-negative patients treated with mastectomy: implications for postmastectomy radiation. Int J Radiat Oncol Biol Phys. 2005;62:1035–9.PubMed
19.
Zurück zum Zitat Beadle BM, Woodward WA, Tucker SL, et al. Ten-year recurrence rates in young women with breast cancer by locoregional treatment approach. Int J Radiat Oncol Biol Phys. 2009;73:734–44.PubMed Beadle BM, Woodward WA, Tucker SL, et al. Ten-year recurrence rates in young women with breast cancer by locoregional treatment approach. Int J Radiat Oncol Biol Phys. 2009;73:734–44.PubMed
20.
Zurück zum Zitat Truong PT, Jones SO, Kader HA, et al. Patients with T1 to T2 breast cancer with one to three positive nodes have higher local and regional recurrence risks compared with node-negative patients after breast-conserving surgery and whole-breast radiotherapy. Int J Radiat Oncol Biol Phys. 2009;73:357–64.PubMed Truong PT, Jones SO, Kader HA, et al. Patients with T1 to T2 breast cancer with one to three positive nodes have higher local and regional recurrence risks compared with node-negative patients after breast-conserving surgery and whole-breast radiotherapy. Int J Radiat Oncol Biol Phys. 2009;73:357–64.PubMed
21.
Zurück zum Zitat Yildirim E, Berberoglu U. Can a subgroup of node-negative breast carcinoma patients with T1–2 tumor who may benefit from Postmastectomy radiotherapy be identified? Int J Radiat Oncol Biol Phys. 2007;68:1024–9.PubMed Yildirim E, Berberoglu U. Can a subgroup of node-negative breast carcinoma patients with T1–2 tumor who may benefit from Postmastectomy radiotherapy be identified? Int J Radiat Oncol Biol Phys. 2007;68:1024–9.PubMed
22.
Zurück zum Zitat Olivotto IA, Truong PT, Chua B. Postmastectomy radiation therapy: who needs it? J Clin Oncol. 2004;22:4237–9.CrossRefPubMed Olivotto IA, Truong PT, Chua B. Postmastectomy radiation therapy: who needs it? J Clin Oncol. 2004;22:4237–9.CrossRefPubMed
23.
Zurück zum Zitat Taylor ME, Haffty BG, Rabinovitch R, et al. ACR appropriateness criteria on postmastectomy radiotherapy expert panel on radiation oncology-breast. Int J Radiat Oncol Biol Phys. 2009;73:997–1002.PubMed Taylor ME, Haffty BG, Rabinovitch R, et al. ACR appropriateness criteria on postmastectomy radiotherapy expert panel on radiation oncology-breast. Int J Radiat Oncol Biol Phys. 2009;73:997–1002.PubMed
25.
Zurück zum Zitat Loftus LS, Laronga C. Evaluating patients with chronic pain after breast cancer surgery. JAMA. 2009;302:2034–5.CrossRefPubMed Loftus LS, Laronga C. Evaluating patients with chronic pain after breast cancer surgery. JAMA. 2009;302:2034–5.CrossRefPubMed
26.
Zurück zum Zitat Gartner R, Jensen MJ, Nielsen J, et al. Prevalence of and factors associated with persistent pain following breast cancer surgery. JAMA. 2009;302:1985–92.CrossRefPubMed Gartner R, Jensen MJ, Nielsen J, et al. Prevalence of and factors associated with persistent pain following breast cancer surgery. JAMA. 2009;302:1985–92.CrossRefPubMed
27.
Zurück zum Zitat MacDonald SM, Abi-Raad RF, Alm El-Din MA, et al. Chest wall radiotherapy: middle ground for treatment of patients with one to three positive lymph nodes after mastectomy. Int J Radiat Oncol Biol Phys. 2009;75:1297–303.PubMed MacDonald SM, Abi-Raad RF, Alm El-Din MA, et al. Chest wall radiotherapy: middle ground for treatment of patients with one to three positive lymph nodes after mastectomy. Int J Radiat Oncol Biol Phys. 2009;75:1297–303.PubMed
28.
Zurück zum Zitat Kronowitz SJ, Robb GL. Radiation therapy and breast reconstruction: a critical review of the literature. Plast Reconstr Surg. 2009;124:395–408.CrossRefPubMed Kronowitz SJ, Robb GL. Radiation therapy and breast reconstruction: a critical review of the literature. Plast Reconstr Surg. 2009;124:395–408.CrossRefPubMed
29.
Zurück zum Zitat Kunkler IH, Canney P, van Tienhoven G, and Russell NS. Elucidating the role of chest wall irradiation in “intermediate-risk” breast cancer: the MRC/EORTC SUPREMO trial. Clin Oncol (R Coll Radiol). 2008;20:31–4. Kunkler IH, Canney P, van Tienhoven G, and Russell NS. Elucidating the role of chest wall irradiation in “intermediate-risk” breast cancer: the MRC/EORTC SUPREMO trial. Clin Oncol (R Coll Radiol). 2008;20:31–4.
30.
Zurück zum Zitat Kyndi M, Sørensen FB, Knudsen H, et al. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J Clin Oncol. 2008;26:1419–26.CrossRefPubMed Kyndi M, Sørensen FB, Knudsen H, et al. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J Clin Oncol. 2008;26:1419–26.CrossRefPubMed
31.
Zurück zum Zitat Mamounas EP, Tang G, Fisher B, et al. Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor–positive breast cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol. 2010;28:1677–83. doi:10.1200/JCO.2009.23.7610 CrossRefPubMed Mamounas EP, Tang G, Fisher B, et al. Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor–positive breast cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol. 2010;28:1677–83. doi:10.​1200/​JCO.​2009.​23.​7610 CrossRefPubMed
Metadaten
Titel
Present-Day Locoregional Control in Patients with T1 or T2 Breast Cancer with 0 and 1 to 3 Positive Lymph Nodes After Mastectomy Without Radiotherapy
verfasst von
Ranjna Sharma, MD
Isabelle Bedrosian, MD
Anthony Lucci, MD
Rosa F. Hwang, MD
Loren L. Rourke, MD
Wei Qiao, MS
Thomas A. Buchholz, MD
Steven J. Kronowitz, MD
Savitri Krishnamurthy, MD
Gildy V. Babiera, MD
Ana M. Gonzalez-Angulo, MD
Funda Meric-Bernstam, MD
Elizabeth A. Mittendorf, MD
Kelly K. Hunt, MD
Henry M. Kuerer, MD, PhD, FACS
Publikationsdatum
01.11.2010
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 11/2010
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-010-1089-x

Weitere Artikel der Ausgabe 11/2010

Annals of Surgical Oncology 11/2010 Zur Ausgabe

Healthcare Policy and Outcomes

Trends in Centralization of Cancer Surgery

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.